Globally reducing the levels of the transcription factor FLI1 in the MRL/lpr and NZM2410 lupus mouse models significantly improves disease by decreasing autoantibody production and increasing survival [5,6,37]. Here, FLI1 is linked to systemic lupus erythematosus.